Matches in Wikidata for { <http://www.wikidata.org/entity/Q50044893> ?p ?o ?g. }
- Q50044893 description "2018 nî lūn-bûn" @default.
- Q50044893 description "2018年の論文" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年学术文章" @default.
- Q50044893 description "2018年學術文章" @default.
- Q50044893 description "2018年學術文章" @default.
- Q50044893 description "2018年學術文章" @default.
- Q50044893 description "2018年學術文章" @default.
- Q50044893 description "2018年學術文章" @default.
- Q50044893 description "2018년 논문" @default.
- Q50044893 description "article científic" @default.
- Q50044893 description "article scientific" @default.
- Q50044893 description "article scientifique" @default.
- Q50044893 description "articol științific" @default.
- Q50044893 description "articolo scientifico" @default.
- Q50044893 description "artigo científico" @default.
- Q50044893 description "artigo científico" @default.
- Q50044893 description "artigo científico" @default.
- Q50044893 description "artikel ilmiah" @default.
- Q50044893 description "artikull shkencor" @default.
- Q50044893 description "artikulong pang-agham" @default.
- Q50044893 description "artykuł naukowy" @default.
- Q50044893 description "artículo científico publicado en 2018" @default.
- Q50044893 description "artículu científicu" @default.
- Q50044893 description "bilimsel makale" @default.
- Q50044893 description "bài báo khoa học" @default.
- Q50044893 description "naučni članak" @default.
- Q50044893 description "scienca artikolo" @default.
- Q50044893 description "scientific article published in February 2018" @default.
- Q50044893 description "scientific article published in February 2018" @default.
- Q50044893 description "scientific article published in February 2018" @default.
- Q50044893 description "teaduslik artikkel" @default.
- Q50044893 description "tieteellinen artikkeli" @default.
- Q50044893 description "tudományos cikk" @default.
- Q50044893 description "vedecký článok" @default.
- Q50044893 description "vetenskaplig artikel" @default.
- Q50044893 description "videnskabelig artikel" @default.
- Q50044893 description "vitenskapelig artikkel" @default.
- Q50044893 description "vitskapeleg artikkel" @default.
- Q50044893 description "vědecký článek" @default.
- Q50044893 description "wetenschappelijk artikel" @default.
- Q50044893 description "wissenschaftlicher Artikel" @default.
- Q50044893 description "επιστημονικό άρθρο" @default.
- Q50044893 description "мақолаи илмӣ" @default.
- Q50044893 description "наукова стаття, опублікована в лютому 2018" @default.
- Q50044893 description "научна статия" @default.
- Q50044893 description "научная статья" @default.
- Q50044893 description "научни чланак" @default.
- Q50044893 description "научни чланак" @default.
- Q50044893 description "מאמר מדעי" @default.
- Q50044893 description "مقالة علمية نشرت في فبراير 2018" @default.
- Q50044893 description "ফেব্রুয়ারি ২০১৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q50044893 description "บทความทางวิทยาศาสตร์" @default.
- Q50044893 description "სამეცნიერო სტატია" @default.
- Q50044893 name "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs)." @default.
- Q50044893 name "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events" @default.
- Q50044893 type Item @default.
- Q50044893 label "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs)." @default.
- Q50044893 label "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events" @default.
- Q50044893 prefLabel "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs)." @default.
- Q50044893 prefLabel "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events" @default.
- Q50044893 P1433 Q50044893-6CFD25DD-2599-4EA9-BC0D-90E22E6F5BB1 @default.
- Q50044893 P1476 Q50044893-51C2572D-E07D-4EA1-9571-18CB16184107 @default.
- Q50044893 P2093 Q50044893-00B6B8E8-7C55-4E94-9032-A48FE195D5FB @default.
- Q50044893 P2093 Q50044893-15A85B32-A8CE-426B-A7F3-370B5D2D20C1 @default.
- Q50044893 P2093 Q50044893-21B895F3-CE2B-4B42-B8F9-7D07FD843574 @default.
- Q50044893 P2093 Q50044893-352C31CC-4CD0-4445-952E-F3FEC37F1209 @default.
- Q50044893 P2093 Q50044893-3D23DB6A-3AFF-47B2-A44F-91160B801B77 @default.
- Q50044893 P2093 Q50044893-92343B98-EEC9-4DC4-9633-332E0A96C5EF @default.
- Q50044893 P2093 Q50044893-B0FC4599-AD68-40CC-845D-8410F1250DC4 @default.
- Q50044893 P2093 Q50044893-C28CD4D6-8747-4CD3-9766-1A3436EC7AE3 @default.
- Q50044893 P2093 Q50044893-C586398A-D32F-407D-A493-77AC8028B41D @default.
- Q50044893 P2093 Q50044893-F014C631-9FA9-4114-B321-429FC009F142 @default.
- Q50044893 P2093 Q50044893-F3F82584-0A4E-4451-A22E-B715DD65E777 @default.
- Q50044893 P2093 Q50044893-F400D3B7-8202-43E3-B7B5-DAEF4524D601 @default.
- Q50044893 P2093 Q50044893-F7AAEE77-495D-4688-8BD2-1A064D9077D5 @default.
- Q50044893 P304 Q50044893-B0B687F3-A1ED-4A67-A5F2-6A5A9FCD9691 @default.
- Q50044893 P31 Q50044893-29556672-CE1F-485A-973C-32EDC156397B @default.
- Q50044893 P356 Q50044893-11502CC0-6537-4677-841A-95E07804C70F @default.
- Q50044893 P433 Q50044893-BF3612D3-E919-435D-AFC1-5C9AEE947313 @default.
- Q50044893 P478 Q50044893-CDA07DDD-0742-4E7C-A822-AF2736C166EA @default.
- Q50044893 P50 Q50044893-AA4FA7E9-5188-4B74-BB2C-643F3F4934A7 @default.
- Q50044893 P50 Q50044893-C99F24DE-960C-4BDA-BBC5-20AAE2C5073C @default.
- Q50044893 P50 Q50044893-D7806DD0-65E8-4357-8A6B-D18C1B519A9B @default.
- Q50044893 P50 Q50044893-F935C18D-0023-42E1-8980-4C588784FBA1 @default.
- Q50044893 P577 Q50044893-D2A928AE-26C9-48E8-AF95-05AC49317A99 @default.
- Q50044893 P698 Q50044893-22413EB5-5795-447C-B7DB-D5C29920067E @default.
- Q50044893 P921 Q50044893-82D2DA6B-196C-4FF0-BF34-B4D59C4172C1 @default.
- Q50044893 P921 Q50044893-CC21E081-57F2-4F14-A91F-5BC5EDF889DE @default.
- Q50044893 P356 2326-6066.CIR-17-0220 @default.
- Q50044893 P698 29437040 @default.
- Q50044893 P1433 Q26841983 @default.
- Q50044893 P1476 "Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs)." @default.
- Q50044893 P2093 "Bradley McGregor" @default.
- Q50044893 P2093 "Craig K Norton" @default.
- Q50044893 P2093 "David F McDermott" @default.